Hepatocellular carcinoma
hcc · society: AASLD
← back to Gastroenterology & Hepatology
Summary
AASLD 2023 Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma updates prior recommendations to reflect ultrasound plus AFP for surveillance, expanded surgical indications (including selected BCLC-B and minimally invasive resection with mild portal hypertension), incorporation of immune checkpoint inhibitor-based combinations (atezolizumab/bevacizumab, durvalumab/tremelimumab) as preferred first-line systemic therapy, and explicit recommendations for multidisciplinary care and advance care planning. The BCLC 2022 framework is endorsed for staging, and LI-RADS is the recommended imaging diagnostic algorithm in at-risk patients.
Current guideline: AASLD 2023 HCC Guidance · 
download Anki sub-deck
Versions
- 2023 · AASLD — AASLD 2023 HCC Guidance